Anyone else fw Curium

Curium extends partnership with NRG I PALLAS for Lu-177 production in Petten, benefiting 100,000 patients globally over the next five years. 'A game changer for NETs and prostate cancer,' says Ciril Faia, CEO SPECT Europe. curiumpharma.com/2024/05/29/cur…

Ditch locked staking! Bluzelle Exchange & CURIUM DePINs = flexible staking for YOU. Earn rewards & stay liquid on your crypto. Power to the people! #Bluzelle #CURIUM #DeFi #Staking #cryptocurrency .

We wrapped up an incredible journey at the 2024 St. Louis Triathlon! 🏊‍♂️🚴‍♀️🏃‍♂️ Over 123 Curium employees and their families pushed boundaries and embraced challenges. Congrats to all participants and our medal winners!

Join Curium at SNMMI 2024 in Toronto from June 8-11! Visit us at booth #839 to discover the latest in #nuclearmedicine and discuss our groundbreaking #clinicaltrials . Don't miss out on exploring the future of healthcare with our expert team!

curiumpharma.com/snmmi-annual-m…

PYLCLARI® is now available in Germany, marking a breakthrough in prostate cancer diagnosis. Developed to identify PSMA-positive prostate cancer lesions, this cutting-edge tracer offers advanced imaging solutions. Read full press release, here: curiumpharma.com/2024/05/06/ger…

Curium Beach 🇨🇾

Turned into another beautiful day 🙌🏼

Curium devant les infos :

US Supreme Court reverses Colorado's rejection of putting Trump on the ballot. Per Curium opinion said it is up to Congress to enforce 14th Amendment.
supremecourt.gov/opinions/23pdf…

Did you know there is a new way to stay connected with Curium? It's your gateway to staying informed about all the latest developments and news in nuclear medicine!

Sign up to stay connected with Curium: curiumpharma.com/stay-connected/

A major update for Curium Life. Our AI algorithm to detect sarcopenia in abdominal CT scans is finally in the market. Aarthi Scans & Labs has started giving reports which talk about sarcopenia in patients with major abdominal conditions and cancer. Thrilled about the potential impact on

We are excited to share the successful enrollment in our Phase 3 SOLAR trials marking a significant step for Curium. Read the full press release here: curiumpharma.com/2024/04/23/pat…

Excited to contribute to the conversation on women's career growth in radiopharmaceuticals with IAEA NA. Our Trading Business Manager in Europe, Julia Lepert, offered key insights on partnership navigation. At Curium, we prioritize diversity, innovation, and empowering our team.

Second paper of the day from Lawrence Livermore National Laboratory on heavy #Element chemistry.
A new curium compound is born!☢️⚡🌈
#POMNews #ActinideNews
Now in Chemical Communications (Open access), pubs.rsc.org/en/content/art…
DOE Office of Science DOE Early Career @NNSAnews
#felements #radiochemistry

Programmation spéciale pour la relâche sur ICI EXPLORA ⤵️
lepetitseptieme.ca/2024/02/22/pro…
#Curium #LeGrosLaboratoire

Join us for a symposium on Piflufolastat [¹⁸F] PET/CT in #prostatecancer with Professor Gary Cook from King's College London. Date: May 14th, 8:00 am. Limited spots available! Register now at [email protected].

Bluzelle Announces Curium, a Miner Pool App to Allow Anyone to Earn BLZ #blockchain -development
buff.ly/49KiBHD

✈️On time airports and Airlines Rankings 2023 : Curium

📌Did u know that hyderabad and Bengaluru airports ranked 2nd and 3rd in the global rankings for on time performance by Curium

👉What did u like and dislike about these airports?

#ccgeek #ccgeek s #AvGeek #AvGeek s

Did you know Curium is driving innovations nuclear medicine? Join us at booth #839 during SNMMI in Toronto, June 8-11, 2024. Meet our experts and get updates on our Phase 3 ECLIPSE, SOLAR-STAGE, and SOLAR-RECUR trials. Discover our latest innovations! curiumpharma.com/snmmi-annual-m…

Curium is thrilled to announce our agreement to #acquire Eczacıbaşı-Monrol Nuclear Product Co., a leading specialist in #nuclearmedicine - expected to boost our Lu-177 production and global #PET presence, benefiting patients worldwide. curiumpharma.com/2024/04/08/acq…